CYDY > Trump had press conference @ 6:00 this evening on Leronlimab > Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, stated, "As we recently reported, we are working diligently with several governmental agencies throughout the world to provide leronlimab to patients suffering from COVID-19. We believe the statistically significant results for NEWS2 is critical to identifying those patients who are at risk of progressing to a more serious condition. Importantly, in addition to the statistically significant efficacy findings, the safety results from this study were very notable with less SAEs and AEs identified in the leronlimab arm, as compared to placebo. Double-blinded clinical trials that are randomized 2:1, like our study, are very challenging to reach significant results as we demonstrated in a small population of a tough COVID-19 population in which to show efficacy and safety. We are eager to see the capabilities of leronlimab in our Phase 3 clinical trial for the severe-to-critical patient population. Our enrollment is now at 182 and we are very optimistic we will reach 195 by the end of August."
New York Yankees and Duke Basketball
